In focus · trending topic

MIN-101 Phase 3

4 stories · following the connections

Minerva Neurosciences Reports Third Quarter 2017 Financial Results and Business Updates

By Nasdaq OMXNov 6, 2017, 12:30 PM UTC

Minerva Provides Update on Phase 3 Design and Development Strategy for MIN-101

By Nasdaq OMXMay 15, 2017, 12:15 PM UTC

Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA

By Nasdaq OMXMay 15, 2017, 12:01 PM UTC

Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA

By Nasdaq OMXMay 15, 2017, 12:01 PM UTC